Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q1 2026 · 10-Q
Revenue$147.44M$147.44M+41.2% vs Q1 2025 Net Income-$2.49M-$2.49MN/M vs Q1 2025 EPS Diluted-$0.02-$0.02N/M vs Q1 2025 Operating Income-$6,513,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,257,000N/M Margins · derivedOperating margin-4.4%+5.1 pt vs Q1 2025
Net margin-1.7%+17.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end